Cuffe S - Search Results

1

Lung cancer stem cells: The root of resistance.

MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP. MacDonagh L, et al. Among authors: cuffe s. Cancer Lett. 2016 Mar 28;372(2):147-56. doi: 10.1016/j.canlet.2016.01.012. Epub 2016 Jan 18. Cancer Lett. 2016. PMID: 26797015 Review.

2

Cisplatin and gemcitabine in the management of metastatic penile cancer.

Power DG, Galvin DJ, Cuffe S, McVey GP, Mulholland PJ, Farrelly C, Delaney DW, O'Byrne KJ. Power DG, et al. Among authors: cuffe s. Urol Oncol. 2009 Mar-Apr;27(2):187-90. doi: 10.1016/j.urolonc.2007.10.015. Epub 2008 Feb 4. Urol Oncol. 2009. PMID: 18367122

3

Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.

Gately K, Al-Alao B, T Dhillon, Mauri F, Cuffe S, Seckl M, O'Byrne K. Gately K, et al. Among authors: cuffe s. Lung Cancer. 2012 Feb;75(2):217-22. doi: 10.1016/j.lungcan.2011.06.012. Epub 2011 Jul 30. Lung Cancer. 2012. PMID: 21802763

4

High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.

Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, O'Byrne KJ. Gately K, et al. Among authors: cuffe s. Clin Lung Cancer. 2014 Jan;15(1):58-66. doi: 10.1016/j.cllc.2013.08.005. Epub 2013 Nov 7. Clin Lung Cancer. 2014. PMID: 24210543

5

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.

Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K. Heavey S, et al. Among authors: cuffe s. Cancer Biol Ther. 2014 Oct;15(10):1367-77. doi: 10.4161/cbt.29841. Epub 2014 Jul 15. Cancer Biol Ther. 2014. PMID: 25025901 Free PMC article.

6

The role of DNA repair pathways in cisplatin resistant lung cancer.

O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP. O'Grady S, et al. Among authors: cuffe s. Cancer Treat Rev. 2014 Dec;40(10):1161-70. doi: 10.1016/j.ctrv.2014.10.003. Epub 2014 Oct 18. Cancer Treat Rev. 2014. PMID: 25458603 Review.

7

The emerging role of microRNAs in resistance to lung cancer treatments.

MacDonagh L, Gray SG, Finn SP, Cuffe S, O'Byrne KJ, Barr MP. MacDonagh L, et al. Among authors: cuffe s. Cancer Treat Rev. 2015 Feb;41(2):160-9. doi: 10.1016/j.ctrv.2014.12.009. Epub 2014 Dec 23. Cancer Treat Rev. 2015. PMID: 25592062 Review.

8

Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.

Leon G, MacDonagh L, Finn SP, Cuffe S, Barr MP. Leon G, et al. Among authors: cuffe s. Pharmacol Ther. 2016 Feb;158:71-90. doi: 10.1016/j.pharmthera.2015.12.001. Epub 2015 Dec 17. Pharmacol Ther. 2016. PMID: 26706243 Review.

9

KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.

Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG. Cregan S, et al. Among authors: cuffe s. Int J Oncol. 2016 Mar;48(3):1290-6. doi: 10.3892/ijo.2016.3335. Epub 2016 Jan 13. Int J Oncol. 2016. PMID: 26780987 Free article.

10

Non-coding RNA repertoires in malignant pleural mesothelioma.

Quinn L, Finn SP, Cuffe S, Gray SG. Quinn L, et al. Among authors: cuffe s. Lung Cancer. 2015 Dec;90(3):417-26. doi: 10.1016/j.lungcan.2015.11.002. Epub 2015 Nov 10. Lung Cancer. 2015. PMID: 26791801 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

126 results

Search Page